Zoetis Inc.

ZTS

CIK 0001555280 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$2.39B
↑+3.0% +$70Mvs FY2024 (Q4)
Operating Income
$736M
↑+8.9% +$60Mvs FY2024 (Q4)
Net Income
$603M
↑+3.8% +$22Mvs FY2024 (Q4)
Gross Profit
$1.68B
↑+4.0% +$65Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
27/100
  • Profitability
    0Insufficient data
  • Liquidity
    100Current Ratio 3.03 (above 1.5 = solid)
  • Leverage
    0D/E 2.71 (under 0.5 = conservative)
  • Efficiency
    34Asset Turnover 0.64x (1.0+ = capital-efficient)
  • Growth
    27Revenue YoY +3.0% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project ZTS's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

12%

Trailing 3-yr CAGR was 12.1%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$104.08
Total enterprise IV
$46.20B
Diluted shares
0.44B
Terminal PV
$34.14B (74% of total)
Year-5 FCF
$4.02B
YearProjected FCFDiscounted PV
+1$2.56B$2.32B
+2$2.86B$2.37B
+3$3.21B$2.41B
+4$3.59B$2.45B
+5$4.02B$2.50B
Terminal$54.99B$34.14B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$621M
investment in PP&E
Stock buybacks (TTM)
$1.53B
share count reduction
Stock-based comp (TTM)
$83M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$15.47B
everything owned
Total liabilities
$12.14B
everything owed
Stockholders' equity
$3.33B
shareholder claim
Net debt
$6.96B
LT debt minus cash

Recent performance · 58 quarters

Revenue↑+3.0% +$70M
$2.39B
Net Income↑+3.8% +$22M
$603M
Free Cash Flow↑+6.2% +$43M
$732M

Drill down